Join Professor Vimal as he delves into the critical role of IL-13 as the dominant cytokine in driving Atopic Dermatitis (AD). In this insightful video, he explains how IL-13’s targeted impact on skin inflammation makes it a pivotal therapeutic target in AD. Discover how Ebglyss, with its selective IL-13 inhibition and unique low dissociation rate, is different from other biologics & effectively managing moderate to severe patients with AD aged 12 and above. Learn how this novel approach offers a new first-line injectable biologic that can deliver long-
